SCHEMBL16836615

SCHEMBL16836615

CC(C)(C)OC(=O)N1CCCN(c2nc(C(C)(C)O)cs2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.47
SKP1 P63208 2/20 0.47
SKP2 Q13309 2/20 0.47
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 4/20 0.42
HRH3 Q9Y5N1 2/20 0.41
GBA1 P04062 1/20 0.41
LMNA P02545 4/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PDE10A Q9Y233 1/20 0.40
MAP4K4 O95819 1/20 0.40
CTSB P07858 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8114293 0.87 LMNA (0.55) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL4573137 0.84 CTSB (0.46) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL5231570 0.84 CKS1B (0.47) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL17541646 0.83 HRH3 (0.55) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL16836625 0.82 HRH3 (0.56) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL5231938 0.81 CKS1B (0.48) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL5233223 0.79 LMNA (0.48) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL31539296 0.79 MAPT (0.49) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL2070545 0.79 GBA1 (0.47) CKS1BSKP1SKP2MAPTHRH3
SCHEMBL13129749 0.78 CKS1B (0.46) CKS1BSKP1SKP2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732077-B2 Diazepane orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-15 US disclosed
US-9732077-B2 Diazepane orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-15 US disclosed
US-9732077-B2 Diazepane orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-15 US disclosed
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
WO-2015095111-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed
WO-2015095111-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318923-A1 DIAZEPANE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CRHR1 CKS1B 4153/4885SKP1 3501/4885SKP2 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.